Limits...
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.

Olsson T, Boster A, Fernández Ó, Freedman MS, Pozzilli C, Bach D, Berkani O, Mueller MS, Sidorenko T, Radue EW, Melanson M - J. Neurol. Neurosurg. Psychiatr. (2014)

Bottom Line: The time to first confirmed relapse was increased with ponesimod compared with placebo.Once-daily treatment with ponesimod 10, 20 or 40 mg significantly reduced the number of new T1 Gd+ lesions and showed a beneficial effect on clinical endpoints.NCT01006265.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Neurosciences, Karolinska Institute, Stockholm, Sweden.

Show MeSH

Related in: MedlinePlus

Kaplan–Meier estimate of the time to first confirmed relapse up to week 24 (all-treated analysis set).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4215282&req=5

JNNP2013307282F4: Kaplan–Meier estimate of the time to first confirmed relapse up to week 24 (all-treated analysis set).

Mentions: Ponesimod treatment increased the time to first confirmed relapse compared with placebo within 24 weeks of ponesimod initiation. Figure 4 shows the estimated proportion of patients experiencing their first confirmed relapse over time. The risk of first confirmed relapse was reduced by 58% in the ponesimod 40 mg group (HR 0.42, 95% CI 0.20 to 0.87), 21% in the ponesimod 20 mg group (HR 0.79, 95% CI 0.43 to 1.45) and 36% in the ponesimod 10 mg group (HR 0.64, 95% CI 0.33 to 1.22) compared with placebo.


Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.

Olsson T, Boster A, Fernández Ó, Freedman MS, Pozzilli C, Bach D, Berkani O, Mueller MS, Sidorenko T, Radue EW, Melanson M - J. Neurol. Neurosurg. Psychiatr. (2014)

Kaplan–Meier estimate of the time to first confirmed relapse up to week 24 (all-treated analysis set).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4215282&req=5

JNNP2013307282F4: Kaplan–Meier estimate of the time to first confirmed relapse up to week 24 (all-treated analysis set).
Mentions: Ponesimod treatment increased the time to first confirmed relapse compared with placebo within 24 weeks of ponesimod initiation. Figure 4 shows the estimated proportion of patients experiencing their first confirmed relapse over time. The risk of first confirmed relapse was reduced by 58% in the ponesimod 40 mg group (HR 0.42, 95% CI 0.20 to 0.87), 21% in the ponesimod 20 mg group (HR 0.79, 95% CI 0.43 to 1.45) and 36% in the ponesimod 10 mg group (HR 0.64, 95% CI 0.33 to 1.22) compared with placebo.

Bottom Line: The time to first confirmed relapse was increased with ponesimod compared with placebo.Once-daily treatment with ponesimod 10, 20 or 40 mg significantly reduced the number of new T1 Gd+ lesions and showed a beneficial effect on clinical endpoints.NCT01006265.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Neurosciences, Karolinska Institute, Stockholm, Sweden.

Show MeSH
Related in: MedlinePlus